CAR T-Cells, NK Cells & CAR Macrophages
In this product category, you will find reports and other services providing you with the most uptodate business and competitive intelligence information on chimeric antigen receptor (CAR) T-cells, natural killer (NK) cells and macrophages (CAR-M). The range of products covers industry data as well as in-depth strategic assessment and analysis of engineered CAR T-cell, NK cell & CAR-M technologies, targets, companies and R&D pipeline.
Subscribe to
our newsletters!
Showing all 15 results
- Landscape analysis report and competitor evalulation of claudin 18.2-targeted immunotherapy candidates€ 2150.00
- Competitor evaluation of recombinant antibodies and cellular therapeutics targeting claudin 18.2 as of April 2024€ 430.00
- This product provides basic information on immunotherapeutics in R&D targeting GPC33.€ 300.00
- This product provides basic information on immunotherapy candidates in research and development targeting DLL3.€ 200.00
- This product provides basic information on immunotherapy candidates in research and development targeting B7-H3.€ 300.00
- This product provides basic information on approved therapeutics and therapy candidates in R&D targeting PSMA.€ 400.00
- This product provides basic information on immunotherapy candidates in research and development targeting mesothelin€ 300.00
- This product provides basic information on approved drugs and drug candidates in R&D targeting folate receptor alpha (FRα)€ 300.00
- This report provides a landscape description and analysis of discovery and development of claudin 18.2 (CLDN18.2)-targeted antibody and cell therapy candidates from an industry perspective as of August 2023€ 1720.00
- This report provides a landscape description and analysis of CAR-M platform technologies and stakeholders from an industry perspective as of February 2023€ 1800.00
- This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.€ 1800.00
- The report evaluates opportunities for GPRC5D-targeted drug modalities within the competitive landscape.€ 600.00
- This report describes and analyzes cadherin 17 (CDH17) as a target opportunity for development of effector-enhanced drug modalities€ 400.00
- This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities€ 500.00
- This report provides an overview of CD33-targeted antibody and cell therapies in development for treatment of acute myeloid leukemia (AML)€ 150.00